tacrolimus and Collagen-Diseases

tacrolimus has been researched along with Collagen-Diseases* in 3 studies

Reviews

1 review(s) available for tacrolimus and Collagen-Diseases

ArticleYear
[Immunosuppressants].
    Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:3

    In recent years, novel immunosuppressive drugs applies to various autoimmune diseases and the evidences increase. Since immunosuppressive drugs inhibit nonselectively the whole immune system, there are possibilities that infection may be induced by decreasing the immunity against pathological agents and malignancy may develop by suppressing immune surveillance. In order to use the immunosuppressants safely and effectively, we should obey the indication and dosage, and be familiar with the side effects. It is also important to take informed consent from patients after explaining the benefit and risk. Therefore, the doctors who are going to use immunosuppressive drugs must know well about the indication, the side effects, the metabolism and the action mechanisms of those drugs.

    Topics: Azathioprine; Calcineurin Inhibitors; Collagen Diseases; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Methotrexate; Rheumatic Diseases; Ribonucleosides; Risk Assessment; Tacrolimus

2009

Other Studies

2 other study(ies) available for tacrolimus and Collagen-Diseases

ArticleYear
[Cardiovascular Surgery for Patients Under Immunosuppressive Therapy].
    Kyobu geka. The Japanese journal of thoracic surgery, 2023, Volume: 76, Issue:10

    Immunosuppressive agents including steroids are generally given to patients with collagen disease or organ transplant recipients. Cardiovascular surgery for these patients can potentially associate with increased rate of postoperative infection or wound healing complications. Here, some key points for perioperative management in patients under immunosuppressive therapy are reviewed. Before an elective surgery, steroids need to be tapered down as much as possible, because even small amount of steroid can lead to adverse postoperative outcomes. Withholding Biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors is recommended for stable collagen disease patients. Current guidelines for perioperative management of antirheumatic medication are summarized in Table 1. Perioperative Glucocorticoid management is also required for patients exposed to steroid therapy. Intra-and postoperative steroid cover regimen is shown in Table 2. On the other hand, immunosuppressive therapy should not be discontinued for those after organ transplant and patients with severely active collagen disease. Our experience of kidney transplant recipients who underwent cardiovascular surgery is shown in Table 3. Close monitoring of blood Tacrolimus level is highly important, because it tends to fluctuate after operation and high Tacrolimus level possibly leads to deterioration in renal function. In conclusion, careful perioperative management in cooperation with transplant surgeons and rheumatologists is vital in this clinical setting.

    Topics: Collagen Diseases; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Steroids; Tacrolimus

2023
A case of rheumatoid vasculitis with acquired reactive perforating collagenosis.
    Modern rheumatology, 2019, Volume: 29, Issue:3

    A 55-year-old man with rheumatoid arthritis (RA) presented hyperkeratotic erythematous papules with crusts or blisters on his limbs and buttocks. A histological study showed acquired reactive perforating collagenosis. Soon, skin lesions changed to umbilicated lesions with black necrosis, and the scar from his skin biopsy ulcerated with induration due to rheumatoid vasculitis. Systemic corticosteroids and tacrolimus administration resolved the RA and skin lesions. Rheumatoid vasculitis with acquired reactive perforating collagenosis has not been reported previously.

    Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Collagen Diseases; Humans; Male; Middle Aged; Rheumatoid Vasculitis; Skin; Tacrolimus

2019